GILD

Gilead Sciences stock fell 1.88% to $153.57, underperforming the broader market which gained between 0.58% and 1.05%. The company is scheduled to report earnings on October 29, 2026, with forecasted EPS of $2.16 (down 12.55% year-over-year) and revenue of $7.81 billion (up 0.59%). Despite the recent decline, Gilead maintains a Zacks Rank #2 (Buy) rating with a modest 1.14% upward revision in consensus EPS estimates over the past month.

Gilead Sciences (GILD) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting an upward trend in earnings estimates over the past three months with a 39.1% increase in consensus estimates. The upgrade positions the company in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving business fundamentals and institutional investor buying pressure.

Gilead Sciences has outperformed broader equities this year, climbing nearly 30%, driven by strong financial results and regulatory progress. The company's Q2 revenue reached $7.8 billion (up 10% YoY), with HIV products generating $5.7 billion.

Recent FDA approvals include Bixlenvo for HIV and Hepcludex for hepatitis delta, while Trodelvy received a label expansion for first-line metastatic triple-negative breast cancer treatment. With a solid dividend yield of 2.2% and flagship products like Biktarvy, Gilead appears attractive for long-term investors despite the stock's recent gains.